1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow BT-001: new trials by email Literature Review of BT-001 trials Research Report on BT-001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors BT-001, Pembrolizumab [KEYTRUDA®] - Metastatic Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | Transgene | 31 | 2021-02-25 | 2025-11-21 |
Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Melanoma (1) · Neoplasm Metastasis (1) · Sarcoma (1) · Triple Negative Breast Neoplasms (1) · Vaccinia (1)
Transgene (1)
Belgium (1) · France (1)